BRIEF published on 05/08/2026 at 22:35, 2 months 12 days ago Integrated BioPharma Reports Decrease in Quarterly Revenue Financial Results Revenue Decline Net Loss Operating Loss Contract Manufacturing
PRESS RELEASE published on 05/08/2026 at 22:30, 2 months 12 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026 Integrated BioPharma, Inc. reports $10.1M revenue for Q1 2026, a 27.3% decrease from Q1 2025. Operating loss of $1.1M in Q1 2026. Financial summary provided Financial Results Revenue Quarterly Report Operating Loss Integrated BioPharma
BRIEF published on 02/11/2026 at 22:35, 5 months 9 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 5 months 9 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 8 months 10 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 8 months 10 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 9 months 27 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 9 months 27 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 1 year 2 months ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 1 year 2 months ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
Published on 07/21/2026 at 17:05, 1 hour 18 minutes ago Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice
Published on 07/21/2026 at 15:00, 3 hours 23 minutes ago Four Nines Gold Begins Maiden Drill Program at Hayden Hill
Published on 07/21/2026 at 15:00, 3 hours 23 minutes ago BlackBerry SecuSUITE Secures Renewed NIAP Common Criteria Certification, Reinforcing Leadership in Sovereign Government-Grade Secure Communications
Published on 07/21/2026 at 14:55, 3 hours 28 minutes ago Vulcan Minerals Inc. - Drilling Completed at Carbonear Zinc-Lead SEDEX Project in Newfoundland
Published on 07/21/2026 at 14:30, 3 hours 53 minutes ago Sarama Completes Sale of its West Australian Gold Assets
Published on 07/21/2026 at 18:15, 8 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 33 minutes ago The New Measure of an EV Isn't Range, It's Peace of Mind
Published on 07/21/2026 at 17:40, 43 minutes ago EQS-Adhoc: Airbus to present new mid-term outlook, strengthen commitment to profitable growth and shareholder returns during investor update
Published on 07/21/2026 at 17:37, 46 minutes ago EQS-Adhoc: Branicks Group AG updates the timetable for the publication of its 2025 annual and consolidated financial statements in light of ongoing restructuring negotiations
Published on 07/20/2026 at 18:20, 1 day ago Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day ago Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:40, 1 day ago Mersen selected to supply Ford and Leapmotor with fuses for electric vehicles
